Lenvatinib/Pembrolizumab Demonstrates Continuing Efficacy in Advanced Melanoma
Lenvatinib and pembrolizumab continued to yield meaningful and durable responses in patients with advanced melanoma who had progressed on previous PD-L1 inhibitor treatment.